These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 36174838)

  • 1. The effect of SARS-CoV-2 double vaccination on the outcomes of hemodialysis patients with COVID-19: A meta-analysis.
    Ao G; Li T; Wang Y; Tran C; Gao M; Chen M
    J Infect; 2023 Feb; 86(2):e43-e45. PubMed ID: 36174838
    [No Abstract]   [Full Text] [Related]  

  • 2. Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months.
    Hsu CM; Weiner DE; Manley HJ; Aweh GN; Ladik V; Frament J; Miskulin D; Argyropoulos C; Abreo K; Chin A; Gladish R; Salman L; Johnson D; Lacson EK
    Clin J Am Soc Nephrol; 2022 Mar; 17(3):403-413. PubMed ID: 35144972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humoral response to SARS-CoV-2 vaccination promises to improve the catastrophic prognosis of hemodialysis patients as a result of COVID-19: the COViNEPH Project.
    Tylicki L; Biedunkiewicz B; Dąbrowska M; Ślizień W; Tylicki P; Polewska K; Rosenberg I; Rodak S; Dębska-Ślizień A
    Pol Arch Intern Med; 2021 Sep; 131(9):797-801. PubMed ID: 34351091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Effectiveness and Immunogenicity of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Patients on Hemodialysis.
    Sibbel S; McKeon K; Luo J; Wendt K; Walker AG; Kelley T; Lazar R; Zywno ML; Connaire JJ; Tentori F; Young A; Brunelli SM
    J Am Soc Nephrol; 2022 Jan; 33(1):49-57. PubMed ID: 34789546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients.
    Danthu C; Hantz S; Dahlem A; Duval M; Ba B; Guibbert M; El Ouafi Z; Ponsard S; Berrahal I; Achard JM; Bocquentin F; Allot V; Rerolle JP; Alain S; Touré F
    J Am Soc Nephrol; 2021 Sep; 32(9):2153-2158. PubMed ID: 34135083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
    Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K
    Front Immunol; 2021; 12():704773. PubMed ID: 34220867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical Stepwise Decline of Antibodies against SARS-CoV-2 among Chronic Hemodialysis Patients 180 Days Post Comirnaty Vaccine.
    Levin-Iaina N; Angel-Korman A; Leiba A; Peres E; Bryk G; Rapoport V; Katzir Z; Yagil Y; Brosh-Nissimov T
    Isr Med Assoc J; 2022 May; 24(5):317-319. PubMed ID: 35598056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humoral response to vaccination against SARS-CoV-2 in patients undergoing maintenance hemodialysis.
    Delgado Ureña A; Hernández García E; Varillas Caso DA
    Med Clin (Barc); 2023 Apr; 160(7):321-322. PubMed ID: 36577651
    [No Abstract]   [Full Text] [Related]  

  • 9. Factors associated with anti-SARS-CoV-2 spike antibody titers after a second BNT162b2 mRNA COVID-19 vaccination in Japanese hemodialysis patients.
    Hirai K; Shimotashiro M; Sonoda T; Okumura T; Ookawara S; Morishita Y
    Clin Exp Nephrol; 2022 Sep; 26(9):925-932. PubMed ID: 35426594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 Booster Vaccine Response among Patients Receiving Dialysis.
    Garcia P; Han J; Montez-Rath ME; Sun S; Shang T; Parsonnet J; Chertow GM; Anand S; Schiller B; Abra G
    Clin J Am Soc Nephrol; 2022 Jul; 17(7):1036-1038. PubMed ID: 35383042
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
    Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
    Front Immunol; 2021; 12():690698. PubMed ID: 34276681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral and Cellular Immune Response After a 3-Dose Heterologous SARS-CoV-2 Vaccination Using the mRNA-BNT162b2 and Viral Vector Ad26COVS1 Vaccine in Hemodialysis Patients.
    Davidovic T; Schimpf J; Abbassi-Nik A; Stockinger R; Sprenger-Mähr H; Lhotta K; Zitt E
    Front Immunol; 2022; 13():907615. PubMed ID: 35812459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humoral response to vaccination against SARS-CoV-2 in patients undergoing dialysis.
    Lee YJ; Park BS; Heo CM; Park S; Yu S; Kim YW
    Medicine (Baltimore); 2022 Dec; 101(50):e32152. PubMed ID: 36550899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of COVID-19 Vaccination in Patients With End-Stage Renal Disease Undergoing Maintenance Hemodialysis: The Efficacy of a Mix-and-Match Strategy.
    Park JS; Minn D; Hong S; Jeong S; Kim S; Lee CH; Kim B
    J Korean Med Sci; 2022 Jun; 37(23):e180. PubMed ID: 35698835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination.
    Gonzalez-Perez M; Montes-Casado M; Conde P; Cervera I; Baranda J; Berges-Buxeda MJ; Perez-Olmeda M; Sanchez-Tarjuelo R; Utrero-Rico A; Lozano-Ojalvo D; Torre D; Schwarz M; Guccione E; Camara C; Llópez-Carratalá MR; Gonzalez-Parra E; Portoles P; Ortiz A; Portoles J; Ochando J
    Front Immunol; 2022; 13():845882. PubMed ID: 35401504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment.
    El Karoui K; De Vriese AS
    Kidney Int; 2022 May; 101(5):883-894. PubMed ID: 35176326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humoral Response to Third Dose of SARS-CoV-2 Vaccines in the CKD Spectrum.
    Quiroga B; Soler MJ; Ortiz A; Orero E; Tejedor S; Mantecón CJJ; Gómez Pérez VO; Marín Franco AJ; Alfaro Sánchez C; Puerta Carretero M; Jaldo Rodríguez MT; Carnerero Di Riso MA; Martínez S; González CC; Cervienka M; Macías Carmona N; Arroyo D; Pérez Del Valle KM; de Arriba G; Mazuecos A; Cazorla JM; Pereira M; González Parra E; Sánchez Márquez MG; Lancho Novillo C; Toyos Ruiz C; Aguilar Cervera MC; Muñoz Ramos P; Sánchez Horrillo A; Jimeno Martín I; Toapanta N; Cigarrán Guldris S; Folgueiras López M; Valero San Cecilio R; Villacorta Linaza B; Minguela Pesquera I; Santana Estupiñán R; Zamora R; Soriano S; Muñoz de Bustillo E; Pizarro Sánchez MS; Martínez Puerto AI; Yugueros A; Muñiz Pacios L; Leyva A; Rojas J; Gansevoort RT; de Sequera P;
    Clin J Am Soc Nephrol; 2022 Jun; 17(6):872-876. PubMed ID: 35551070
    [No Abstract]   [Full Text] [Related]  

  • 18. Neutralizing Antibody Activity Against the B.1.617.2 (delta) Variant Before and After a Third BNT162b2 Vaccine Dose in Hemodialysis Patients.
    Benning L; Klein K; Morath C; Bartenschlager M; Kim H; Buylaert M; Reineke M; Töllner M; Nusshag C; Kälble F; Reichel P; Schnitzler P; Zeier M; Süsal C; Bartenschlager R; Schaier M; Speer C
    Front Immunol; 2022; 13():840136. PubMed ID: 35309320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Waning humoral response 6 months after SARS-CoV-2 vaccination with the mRNA-BNT162b2 vaccine in hemodialysis patients: time for a boost.
    Davidovic T; Schimpf J; Abbassi-Nik A; Stockinger R; Sprenger-Mähr H; Lhotta K; Zitt E
    Kidney Int; 2021 Dec; 100(6):1334-1335. PubMed ID: 34656642
    [No Abstract]   [Full Text] [Related]  

  • 20. Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients.
    Melin J; Svensson MK; Albinsson B; Winqvist O; Pauksens K
    BMC Immunol; 2021 Oct; 22(1):70. PubMed ID: 34666683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.